Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Tax loss deal?

<< Previous

Bullboard Posts

Next >>

Comment by Maxmoeon Dec 29, 2020 1:46am

86 Views

Post# 32189606

RE:Tax loss deal?

Please elaborate. Note 18 from last annual report noted huge non capital tax losses from cardiome acquisition . I assume that's what you are referring to? But I noted that cph pays current taxes, so are the tax losses useful to cph or not? There is also the typical bicker with CRA about the tax losses from that transaction. I'm no tax expert by any means but if cph can't use them and CRA disputes them, then who would want to pay anything for them?